You are reading the English version
קרא בעברית
Dihydrotestosterone (DHT) is the single most important hormone in hair loss biology – yet most people who notice thinning hair have never heard of it. DHT is directly responsible for the progressive follicle shrinkage behind androgenetic alopecia, the condition that accounts for over 95% of male pattern baldness and a significant share of female hair thinning. This guide explains exactly how DHT damages follicles at the cellular level, why certain areas of the scalp are vulnerable while others are permanently resistant, and how every effective treatment – from finasteride to hair transplant surgery – works by targeting some point in the DHT pathway.
What Is DHT (Dihydrotestosterone)?
Dihydrotestosterone (DHT) is a potent androgen hormone derived from testosterone through the action of the enzyme 5-alpha reductase, responsible for the progressive follicle miniaturization that causes male and female pattern hair loss.
Testosterone is the precursor. On its own, testosterone has relatively weak binding affinity to androgen receptors. The enzyme 5-alpha reductase converts testosterone into DHT, which binds to androgen receptors with approximately five times greater affinity and dissociates far more slowly.
Two isoforms of 5-alpha reductase exist in human tissue:
- Type I is found primarily in sebaceous (oil) glands and skin. It contributes to scalp DHT but plays a secondary role in follicular miniaturization.
- Type II is concentrated in the outer root sheath of hair follicles and the dermal papilla – the growth center at the base of each follicle. Type II is the dominant driver of hair loss, which is why drugs that selectively inhibit Type II (such as finasteride) effectively slow or halt pattern baldness.
DHT is not inherently harmful. During fetal development, it is essential for male genital formation. During puberty, DHT drives facial hair growth, voice deepening, and body hair development. The paradox: the same hormone that stimulates beard growth simultaneously destroys scalp hair in genetically susceptible individuals.
Intrafollicular DHT concentration – the amount produced locally within the scalp – matters far more than serum levels. Two men can have identical blood DHT yet experience vastly different hair loss, because the critical variable is how much 5-alpha reductase the follicles produce and how many androgen receptors they express.
How DHT Causes Hair Follicle Miniaturization
The mechanism by which DHT destroys follicles is slow and cyclical – spanning years to decades – which is why hair loss appears gradual rather than abrupt.
Step 1 – Conversion. Testosterone enters the dermal papilla. The enzyme 5-alpha reductase (primarily Type II) converts it into DHT within the follicle itself.
Step 2 – Receptor binding. DHT binds to androgen receptors in the dermal papilla cells with five times the affinity of testosterone, triggering a far stronger intracellular signal.
Step 3 – Gene transcription changes. The DHT-receptor complex enters the cell nucleus and upregulates growth-inhibiting proteins (TGF-beta 1, TGF-beta 2, DKK-1) while downregulating growth-promoting signals like IGF-1 and VEGF, reducing blood supply to the follicle.
Step 4 – Anagen shortening. The growth phase shortens progressively. A healthy follicle maintains anagen for two to seven years. Under sustained DHT influence, anagen drops to months, then weeks. Each cycle produces a thinner, shorter hair shaft.
Step 5 – Perifollicular fibrosis. Chronic DHT exposure triggers low-grade inflammation. Collagen deposits constrict the follicle and reduce blood supply – the tipping point between reversible miniaturization and permanent follicle death.
Step 6 – Terminal-to-vellus transition. The follicle produces only a fine, colorless vellus hair invisible to the naked eye. The dermal papilla has shrunk to a fraction of its original size.
Step 7 – Follicle death. The follicle fibroses completely and cannot re-enter anagen. No medical treatment can revive it. Only hair transplant surgery can restore hair by introducing new, DHT-resistant follicles.
The entire process can span 5 to 25 years. Early treatment – before fibrosis becomes irreversible – produces significantly better outcomes than waiting.
Why Some Follicles Are DHT-Sensitive and Others Are Not
DHT circulates systemically through the bloodstream, reaching every follicle on the scalp equally. Yet the frontal hairline and vertex thin while the sides and back remain dense, even in advanced Norwood Stage VII baldness. The explanation is entirely genetic – and it resides within the follicle itself, not its location on the scalp.
Androgen receptor density. Follicles on the top and front of the scalp express significantly higher concentrations of androgen receptors than follicles in the occipital (back) and parietal (side) regions. More receptors means more DHT binding, stronger intracellular signaling, and faster miniaturization.
5-alpha reductase production. DHT-sensitive follicles also produce more 5-alpha reductase locally, creating higher intrafollicular DHT concentrations independent of systemic levels. Occipital follicles produce less of the enzyme, generating lower local DHT regardless of circulating testosterone.
The androgen receptor (AR) gene. The AR gene on the X chromosome is the strongest single genetic predictor of androgenetic alopecia. Variants determine how sensitive a follicle’s receptors are to DHT. Men who inherit high-sensitivity variants from their mother’s X chromosome face substantially greater risk – the origin of the oversimplified belief that “baldness comes from your mother’s side.”
Polygenic inheritance. More than 200 genetic loci have been associated with androgenetic alopecia. While the AR gene is the strongest contributor, autosomal genes influence 5-alpha reductase expression, inflammatory response, and follicle stem cell resilience – explaining why hair loss patterns vary even among brothers with identical maternal genetics.
Donor dominance. The principle of donor dominance – first described by Dr. Norman Orentreich in 1959 – established that a transplanted follicle retains the genetic characteristics of its original site, not its new location. An occipital follicle relocated to the crown remains DHT-resistant permanently. This principle is the biological foundation of every hair transplant procedure performed today.
DHT Levels – Testing and Normal Ranges
Blood testing for DHT can help clinicians assess androgen activity, though serum DHT alone does not predict hair loss severity due to the importance of local follicular receptor sensitivity.
| Marker | Normal Range (Adult Males) | Normal Range (Adult Females) | Test Method | Clinical Relevance to Hair Loss |
|---|---|---|---|---|
| Serum DHT | 30–85 ng/dL | 4–22 ng/dL | Blood draw (LC-MS/MS preferred) | Elevated levels may accelerate miniaturization in genetically susceptible individuals |
| Total Testosterone | 300–1,000 ng/dL | 15–70 ng/dL | Blood draw | Provides context for DHT conversion rate; low T with high DHT suggests elevated 5-AR activity |
| Free Testosterone | 5–21 ng/dL | 0.1–0.85 ng/dL | Blood draw (equilibrium dialysis) | Free T is the fraction available for conversion to DHT |
| DHEA-S | 100–500 mcg/dL | 35–430 mcg/dL | Blood draw | Elevated in adrenal-driven female pattern hair loss |
| Sex Hormone-Binding Globulin (SHBG) | 10–57 nmol/L | 18–144 nmol/L | Blood draw | Low SHBG increases free testosterone available for DHT conversion |
Important caveat: Serum DHT is a population-level indicator, not a diagnostic tool for individual hair loss. A man at 40 ng/dL can experience severe loss with high-sensitivity receptors, while a man at 80 ng/dL may retain full hair with resistant follicles. Scalp biopsy and miniaturization assessment via trichoscopy provide far more accurate diagnostic information than blood work alone.
How to Reduce DHT and Slow Hair Loss
Every evidence-based approach to treating androgenetic alopecia targets the DHT pathway – reducing systemic production, blocking receptor binding, or stimulating growth through DHT-independent mechanisms.
| Method | Mechanism | DHT Reduction | Evidence Level | Typical Results |
|---|---|---|---|---|
| Finasteride (1 mg oral) | Inhibits Type II 5-alpha reductase | ~70% serum reduction | FDA-approved; multiple RCTs | Halts progression in ~90%; regrowth in ~65% at 2 years |
| Dutasteride (0.5 mg oral) | Inhibits Type I and Type II 5-alpha reductase | ~90% serum reduction | Off-label in US; FDA-approved in Japan/South Korea; RCT data | Superior to finasteride in head-to-head trials; greater regrowth |
| Topical Finasteride | Local Type II inhibition at the scalp | ~30–40% serum reduction | Growing clinical data; not yet FDA-approved for hair loss | Similar scalp DHT reduction to oral with lower systemic exposure |
| Minoxidil (topical/oral) | Vasodilator; prolongs anagen (does not reduce DHT) | 0% – DHT-independent | FDA-approved; extensive RCTs | Moderate regrowth; best combined with a DHT blocker |
| Saw Palmetto | Weak 5-alpha reductase inhibition | ~10–15% (estimated) | Limited; small studies, no FDA approval | Modest slowing in mild cases; not comparable to finasteride |
| Pumpkin Seed Oil | Possible mild 5-AR inhibition | Unknown – poorly quantified | One small RCT (76 participants) | Statistically significant but clinically modest improvement |
| Ketoconazole Shampoo (2%) | Topical anti-androgen; reduces scalp DHT locally | Local only – no systemic effect | Moderate; supportive adjunct studies | Reduces inflammation; best as complement to primary treatment |
Finasteride – The Gold Standard DHT Blocker
Finasteride is a selective inhibitor of Type II 5-alpha reductase that reduces serum DHT by approximately 70% at a daily dose of 1 mg. Clinical trials demonstrate it halts further hair loss in roughly 90% of men and produces visible regrowth in approximately 65% over two years of continuous use.
The drug blocks conversion of testosterone to DHT at the enzymatic level without reducing testosterone itself. Steady-state DHT suppression occurs within one to two weeks, but visible hair results require 6 to 12 months due to the length of the hair growth cycle.
Side effects – including decreased libido, erectile changes, and reduced ejaculatory volume – are reported by 2-4% of users in clinical trials, with the majority resolving upon discontinuation. Our complete finasteride guide covers dosing, side effect management, and long-term outcome data.
Dutasteride
Dutasteride inhibits both Type I and Type II isoforms of 5-alpha reductase, reducing serum DHT by approximately 90%. Head-to-head trials demonstrate superior hair count increases compared to finasteride at the 0.5 mg daily dose.
Dutasteride is FDA-approved for benign prostatic hyperplasia (BPH) in the United States but prescribed off-label for hair loss. In Japan and South Korea, it holds regulatory approval specifically for androgenetic alopecia. Its longer half-life (approximately 5 weeks versus 6-8 hours for finasteride) means DHT suppression persists far longer after discontinuation. Our dutasteride guide covers candidacy criteria, dosing protocols, and comparison data.
Natural DHT Blockers – Do They Work?
Saw palmetto, pumpkin seed oil, green tea extract (EGCG), pygeum bark, and stinging nettle root are commonly marketed as natural DHT blockers. The evidence ranges from weak to negligible compared to pharmaceutical-grade 5-alpha reductase inhibitors.
Saw palmetto has the most clinical data. A 2020 meta-analysis found it improved hair density modestly versus placebo but was statistically inferior to finasteride in every direct comparison. Pumpkin seed oil showed a 40% hair count improvement in one small 24-week Korean study of 76 men – a result that has not been replicated independently.
For mild early-stage hair loss in patients who decline pharmaceutical treatment, natural DHT blockers may provide marginal benefit. For moderate to advanced androgenetic alopecia, they are not a substitute for proven medical therapy.
Frequently Asked Questions
Does high testosterone cause hair loss?
Testosterone itself does not directly cause hair loss. DHT – converted from testosterone by 5-alpha reductase – is the active agent. Men with high testosterone but low receptor sensitivity can retain full density, while men with average testosterone but high-sensitivity androgen receptors can experience significant loss.
Can DHT hair loss be reversed?
In early and moderate stages, yes. Finasteride and dutasteride can halt miniaturization and partially reverse it. Once a follicle has fully fibrosed, no medical treatment can revive it – hair transplant surgery becomes the only restoration option.
Do DHT blocker shampoos work?
Ketoconazole shampoo (2%) has modest evidence as an adjunct – it reduces local scalp DHT and inflammation. Over-the-counter “DHT blocker” shampoos containing saw palmetto, biotin, or caffeine have no rigorous evidence supporting meaningful DHT reduction.
Does blocking DHT cause side effects?
Finasteride produces sexual side effects in 2-4% of men in clinical trials. Dutasteride carries a similar profile. The vast majority of side effects resolve upon discontinuation. Detailed data is covered in our finasteride guide.
Is DHT the only cause of hair loss?
No. Telogen effluvium, alopecia areata, traction alopecia, nutritional deficiencies, and thyroid disorders all cause hair loss through DHT-independent mechanisms. Accurate diagnosis is essential before starting treatment.
Can women take DHT blockers?
Finasteride and dutasteride are contraindicated in women who are or may become pregnant. Spironolactone – an androgen receptor blocker – is the most commonly prescribed anti-androgen for female pattern hair loss.
Why DHT-Resistant Hair Makes Transplants Permanent
The permanence of hair transplant results is a direct consequence of follicle biology. Follicles harvested from the occipital donor area are genetically programmed with low androgen receptor density and minimal 5-alpha reductase production. When transplanted to the crown or hairline, they retain their original genetic identity permanently.
This principle – donor dominance – means a transplanted follicle continues producing thick, terminal hair in its new location for life, regardless of surrounding DHT levels. Donor dominance is the reason surgeons evaluate donor area density so carefully during a transplant consultation – the number of DHT-resistant follicles available determines achievable coverage.
For patients combining transplant surgery with ongoing DHT-blocking medication, the result is comprehensive: transplanted follicles provide permanent density in balding areas, while finasteride or dutasteride preserves remaining native hair. This combined approach is detailed in our guide to why transplanted hair is permanent.
You are reading the English version
קרא בעברית